IBD 50 Sep 2026
STOCK ANALYSIS PROJECT · IBD 50 AS PUBLISHED · DATA THROUGH FRI SEP 25, 2026 CLOSE
IBD 50 Screen
All 50 names scored on fundamentals, trend and Monte Carlo risk,
then the top five get a full workup: peer comparison, one-quarter and one-year
forecasts with probabilities, and technical levels.
SPY $771.35 (-1.0% from high, 12M +17%) ·
QQQ $744.5 (-0.6% from high, 12M +25%)
· IBD 50 avg 1Y vol 57% vs SPY
13% ·
Avg MC P(up in 1Y) 56% vs SPY 73%
Top five from the screen
|
Ticker |
Rating |
Price |
1Q target |
P(≥ at 1Q) |
1Y target |
P(≥ at 1Y) |
Score |
|
MU Micron Technology |
BUY |
$1,082 |
$1,180 (+9%) |
43% |
$1,300 (+20%) |
45% |
80 · #1 |
|
ECO Okeanis Eco Tankers |
HOLD |
$77.90 |
$76.00 (-2%) |
49% |
$75.00 (-4%) |
43% |
79 · #2 |
|
NVDA NVIDIA |
BUY |
$225.07 |
$245.00 (+9%) |
36% |
$290.00 (+29%) |
32% |
76 · #3 |
|
HALO Halozyme Therapeutics |
BUY |
$113.90 |
$118.00 (+4%) |
46% |
$130.00 (+14%) |
43% |
75 · #4 |
|
INSW International Seaways |
HOLD |
$105.64 |
$105.00 (-1%) |
47% |
$100.00 (-5%) |
49% |
72 · #5 |
Probabilities come from the Monte Carlo simulation under a
market-neutral drift; see “How the numbers were built”. ECO and INSW targets
are ex-dividend share prices.
Key takeaways
•
Two of
five are crude tankers. ECO
and INSW ride the same Iran-driven rate spike. Treat them as one position; own
one, not both.
•
Micron
reports Wed Sep 30. The
1Q forecast straddles a binary event. The 1-sigma daily move implied by its 79%
volatility is about 5%, and earnings days often run 2–3× that.
•
Gold
miners are resting, not broken. All nine precious-metal names are down 3–16% over the past month
with RSI 44–53, yet every one still trades above its 200-day line.
MU Micron Technology
$1,082 BUY
The cheapest way to own AI data-center spend on forward
earnings. Revenue is up 346% year over year, operating margin is 80%, and the
stock trades under 7× next year's consensus EPS. The cycle, not the business,
is the risk: memory multiples compress at peaks, and Wednesday's report sets
the next leg.
Forecast and probability
|
|
1 quarter |
1 year |
|
Target price |
$1,180 |
$1,300 |
|
Change from
today |
+9.0% |
+20.1% |
|
P(at or above
target at horizon) |
43% |
45% |
|
P(trades at
target first) |
77% |
81% |
|
MC median
price |
$1,104 |
$1,166 |
|
MC P10 – P90 |
$660 – $1,847 |
$423 – $3,209 |
|
P(down 20%+ at
1Y) |
– |
35% |
1Y base case: about 8× forward EPS of roughly $160, or $1,300.
Consensus mean is $1,516 from 46 analysts, but the range runs $361 to $2,200,
which says the Street disagrees about where the cycle peaks. Simulation
volatility 79%, drift +7.6% a year.
Monte Carlo price fan, next 12 months (log scale)
Technical analysis
One year, weekly closes with 50- and 200-day averages ·
trend checks 6/7
Uptrend intact: price is above the 20-, 50- and 200-day
averages, RSI 63, MACD histogram positive. The 50-day has flattened (−1.6% over
a month) after the June–July blow-off and a 39% peak-to-trough shakeout. Volume
into earnings is light at 0.75× its 50-day average. First resistance is the
60-day high at $1,109, then the $1,255 record. Support sits at the 50-day
($942), then the $738 July low.
|
Key level |
Value |
|
Resistance |
$1,109 · $1,255 |
|
Support |
$942 (50d) · $738 |
|
Bollinger 20d |
$882 – $1,106 |
|
RSI 14 / MACD |
63 / positive |
|
Off 52-wk high |
−13.8% |
|
Realized vol,
1Y |
80.5% |
Fundamentals
|
Metric |
Value |
|
Revenue,
trailing 12 mo |
$90.3B |
|
Revenue growth
y/y |
+346% |
|
Operating
margin |
80.4% |
|
Return on
equity |
66.6% |
|
Trailing /
forward P/E |
24.5× / 6.8× |
|
PEG |
0.16 |
|
Free cash
flow, TTM |
$7.6B |
|
Cash / debt |
$26.0B / $6.4B |
|
Q4 FY26 guide
(Sep 30) |
$50B ±1B rev, $31 ±1 EPS |
|
Analyst mean
target (n) |
$1,516 (46) |
Peer comparison
|
Ticker |
Price |
Mkt cap |
Fwd P/E |
Rev growth |
Op margin |
3M |
12M |
1Y vol |
To target |
|
MU |
$1,082 |
$1.22T |
6.8× |
+346% |
+80% |
-4% |
+590% |
81% |
+40% |
|
SNDK |
$1,778 |
$260.3B |
6.7× |
+372% |
+79% |
-15% |
+1731% |
115% |
+20% |
|
WDC |
$456.81 |
$164.7B |
14.4× |
+44% |
+44% |
-22% |
+327% |
80% |
+46% |
|
STX |
$916.83 |
$208.5B |
16.6× |
+49% |
+43% |
+2% |
+322% |
75% |
+23% |
Memory and storage peers. SK Hynix and Samsung trade in Korea
and are not shown. Micron matches SanDisk's single-digit forward multiple with
a higher margin and far lower volatility, and it fell less than SNDK and WDC
over the past three months.
Catalysts
•
Q4 FY26
report Wed Sep 30: guide was $50B revenue and $31 EPS; consensus sits near the
top of that range
•
HBM4 now
shipping into NVIDIA platforms; 2026 HBM supply sold out
•
16
long-term customer agreements with more than $22B of cash commitments through
2030
Risks
•
Guide-dependent:
with consensus at the top of the range, an in-line Q1 FY27 outlook could sell
off
•
Taiwan
union demanding 15% of operating profit, with a strike vote in early October
•
Tariffs on
semiconductors, Netlist DDR5 patent suit, and 3.3 beta to the S&P 500
Screen scorecard
|
Component |
Score |
|
Composite
score |
80 / 100 |
|
Fundamentals |
39 / 40 |
|
Technicals |
32 / 35 |
|
Risk |
2 / 15 |
|
IBD rank |
8 / 10 |
|
Beta to
S&P 500 |
3.30 |
DEEP DIVE · VLCC / SUEZMAX CRUDE TANKERS · SCREEN #2 OF 50 · IBD
RANK 2
ECO Okeanis Eco Tankers
$77.90 HOLD
A pure play on spot VLCC rates, which spiked past $1 million a
day on the Arabian Gulf–China route on Sep 16 as the Iran conflict disrupted
shipping. Q2 was the best quarter in company history, and Q3 VLCC bookings near
$207,000 a day point to another strong one. The question is how long the
disruption lasts. The stock pays out about 90% of earnings, so most of the
return arrives as cash rather than price.
Forecast and probability
|
|
1 quarter |
1 year |
|
Target price |
$76.00 |
$75.00 |
|
Change from
today |
-2.4% |
-3.7% |
|
Est. total
return incl. dividends |
+5% |
+18% |
|
P(at or above
target at horizon) |
49% |
43% |
|
MC median
price |
$75.58 |
$68.72 |
|
MC P10 – P90 |
$57.03 – $100 |
$39.12 – $121 |
|
P(down 20%+ at
1Y) |
– |
41% |
Targets are ex-dividend share prices. Expected total return is
about +5% for the quarter and +18% for the year, including my dividend estimate
of roughly $6 next quarter and $17 over 12 months. The single covering analyst
targets $75. Simulation volatility 44%, drift -12.3% a year.
Monte Carlo price fan, next 12 months (log scale)
Technical analysis
One year, weekly closes with 50- and 200-day averages ·
trend checks 6/7
Momentum is rolling over. The stock spiked to $87.31 in
mid-September with the rate headlines, then gave back 11%. Volume is 1.7×
normal on the pullback, and the MACD histogram has turned negative. The trend
is still up: price is above a steep 50-day ($66.8) and 200-day ($52). The upper
Bollinger band at $88 marks the spike high; the lower band and 50-day at $63–67
are the first real support.
|
Key level |
Value |
|
Resistance |
$87.3 (Sep high) |
|
Support |
$66.8 (50d) · $63.2 (BB) |
|
Bollinger 20d |
$63.2 – $88.3 |
|
RSI 14 / MACD |
59 / negative |
|
Off 52-wk high |
−10.8% |
|
Realized vol,
1Y |
43.4% |
Fundamentals
|
Metric |
Value |
|
Q2 2026 adj.
EPS |
$5.91 |
|
Q2 dividend
(payout) |
$5.25 (~90%) |
|
Q3 VLCC days
fixed |
48% at ~$207k/day |
|
Revenue growth
y/y |
+239% |
|
Operating
margin |
75% |
|
Trailing /
forward P/E |
7.2× / 13.1× |
|
EV / EBITDA |
7.4× |
|
Fleet |
18 ships, avg 5.6 yrs |
|
Net
loan-to-value |
<25% |
|
Analyst target
(n) |
$75 (1) |
Peer comparison
|
Ticker |
Price |
Mkt cap |
Fwd P/E |
Rev growth |
Op margin |
3M |
12M |
1Y vol |
To target |
|
ECO |
$77.90 |
$3.0B |
13.1× |
+239% |
+75% |
+56% |
+164% |
43% |
-4% |
|
INSW |
$105.64 |
$5.2B |
16.5× |
+140% |
+64% |
+33% |
+123% |
39% |
+1% |
|
FRO |
$47.73 |
$10.6B |
10.4× |
+97% |
+66% |
+34% |
+107% |
43% |
+6% |
|
TNK |
$94.07 |
$3.3B |
8.6× |
+63% |
+50% |
+38% |
+79% |
39% |
-0% |
|
DHT |
$21.78 |
$3.5B |
10.2× |
+96% |
+71% |
+23% |
+77% |
37% |
+0% |
|
STNG |
$81.49 |
$4.1B |
15.1× |
+78% |
+60% |
+12% |
+41% |
36% |
+19% |
|
NAT |
$7.72 |
$1.6B |
17.0× |
+98% |
+52% |
+32% |
+141% |
40% |
-16% |
ECO has the most VLCC spot leverage in the group and the
strongest 3-month run. Frontline (FRO) is the larger, more liquid alternative.
Most peers trade within a few percent of their consensus targets, which shows
how far prices have run ahead of analyst models.
Catalysts
•
Q3 dividend
declared with results in early November; which could exceed Q2's $5.25
•
Atlantic-to-Asia
VLCC liftings up to about 35% of volume from 22%, which lengthens voyages
•
Winter
seasonal strength on top of disruption
Risks
•
A ceasefire
or reopened routes would cut rates quickly; forward P/E already assumes
normalization
•
Heavy spot
exposure: 52% of fleet days still open
•
Ex-dividend
drops of $5–7 each quarter pull the share price down mechanically
Screen scorecard
|
Component |
Score |
|
Composite
score |
79 / 100 |
|
Fundamentals |
32 / 40 |
|
Technicals |
27 / 35 |
|
Risk |
10 / 15 |
|
IBD rank |
10 / 10 |
|
Beta to
S&P 500 |
0.33 |
NVDA NVIDIA
$225.07 BUY
Still the core AI holding, and now priced like a value stock on
forward numbers: 14× next year's EPS with revenue doubling. Management guided
fiscal 2028 revenue up about 70% on a supply-constrained basis. The stock is up
27% in a year while earnings more than doubled, which is what compressed the
multiple.
Forecast and probability
|
|
1 quarter |
1 year |
|
Target price |
$245.00 |
$290.00 |
|
Change from
today |
+8.9% |
+28.8% |
|
P(at or above
target at horizon) |
36% |
32% |
|
P(trades at
target first) |
63% |
55% |
|
MC median
price |
$230 |
$241 |
|
MC P10 – P90 |
$180 – $292 |
$150 – $394 |
|
P(down 20%+ at
1Y) |
– |
22% |
1Y base case: about 18.5× forward EPS of $15.68, or $290.
Consensus mean is $328 from 59 analysts. I sit below it because hyperscaler
custom silicon caps the multiple. Simulation volatility 38%, drift +7.3% a
year.
Monte Carlo price fan, next 12 months (log scale)
Technical analysis
One year, weekly closes with 50- and 200-day averages ·
trend checks 7/7
The cleanest chart in the top five: all seven trend checks pass.
Price $225 sits over a rising 50-day ($216) and 200-day ($199.5). Bollinger
bands have narrowed to $211–$233, a squeeze that usually resolves with a larger
move. A weekly close above $236.5 would be a breakout to new highs. Below $216,
look for $199–$190.
|
Key level |
Value |
|
Resistance |
$234.8 · $236.5 (high) |
|
Support |
$216 (50d) · $199.5 (200d) |
|
Bollinger 20d |
$210.8 – $232.7 |
|
RSI 14 / MACD |
55 / positive |
|
Off 52-wk high |
−4.8% |
|
Realized vol,
1Y |
37.6% |
Fundamentals
|
Metric |
Value |
|
Revenue,
trailing 12 mo |
$303B |
|
Revenue growth
y/y |
+106% |
|
Q2 FY27
revenue |
$96.2B (DC $89.0B) |
|
Gross /
operating margin |
75.0% / 66.2% |
|
Return on
equity |
117% |
|
Trailing /
forward P/E |
28.5× / 14.4× |
|
PEG |
0.47 |
|
Q3 FY27 guide |
$108B ±2%, GM 74% |
|
Capital
return, Q2 |
$20B buyback |
|
Analyst mean
target (n) |
$328 (59) |
Peer comparison
|
Ticker |
Price |
Mkt cap |
Fwd P/E |
Rev growth |
Op margin |
3M |
12M |
1Y vol |
To target |
|
NVDA |
$225.07 |
$5.43T |
14.4× |
+106% |
+66% |
+17% |
+27% |
38% |
+46% |
|
AVGO |
$352.81 |
$1.68T |
18.2× |
+86% |
+54% |
-3% |
+6% |
47% |
+51% |
|
TSM |
$450.61 |
$2.34T |
20.6× |
+36% |
+60% |
+4% |
+63% |
40% |
+23% |
|
AMD |
$630.63 |
$1.03T |
40.5× |
+50% |
+17% |
+21% |
+291% |
72% |
-2% |
|
MRVL |
$261.94 |
$235.4B |
38.8× |
+37% |
+17% |
-2% |
+215% |
78% |
+10% |
|
INTC |
$123.00 |
$650.2B |
59.6× |
+25% |
+12% |
-4% |
+247% |
76% |
-5% |
NVIDIA has the fastest growth and the lowest forward P/E in its
peer group. AMD has tripled and now trades above its consensus target.
Catalysts
•
Q3 FY27
report Tue Nov 17; guide of $108B beat the $104B Street estimate
•
Vera Rubin
began shipping in August, aimed at inference and agentic workloads
•
FY2028
revenue growth of about 70% guided as supply-constrained
Risks
•
Custom
chips at Amazon, Alphabet, Microsoft and Meta displacing some workloads
•
Guide
assumes zero China data-center revenue; policy could cut either way
•
$279B of
supply commitments, mostly memory, if demand turns
Screen scorecard
|
Component |
Score |
|
Composite
score |
76 / 100 |
|
Fundamentals |
33 / 40 |
|
Technicals |
25 / 35 |
|
Risk |
14 / 15 |
|
IBD rank |
3 / 10 |
|
Beta to
S&P 500 |
1.89 |
DEEP DIVE · DRUG-DELIVERY ROYALTIES · SCREEN #4 OF 50 · IBD RANK
10
HALO Halozyme Therapeutics
$113.90 BUY
A royalty stream on subcutaneous versions of blockbuster
biologics, priced at 11× forward earnings while growing revenue 48%. Q2 beat
EPS by $0.49 and the August gap-up has held. The discount exists because the
core ENHANZE patents run out later this decade. The newer MDASE platform, and
the Keytruda subcutaneous fight with Merck, decide how much royalty life is
left after that.
Forecast and probability
|
|
1 quarter |
1 year |
|
Target price |
$118.00 |
$130.00 |
|
Change from
today |
+3.6% |
+14.1% |
|
P(at or above
target at horizon) |
46% |
43% |
|
P(trades at
target first) |
79% |
74% |
|
MC median
price |
$115 |
$122 |
|
MC P10 – P90 |
$90.50 – $151 |
$73.53 – $209 |
|
P(down 20%+ at
1Y) |
– |
23% |
1Y base case: about 12.5× next year's EPS of $10.39, or $130.
The consensus mean of $99.6 from 9 analysts sits below the price because
targets have not caught up with the August rerating. Simulation volatility 41%,
drift +7.7% a year.
Monte Carlo price fan, next 12 months (log scale)
Technical analysis
One year, weekly closes with 50- and 200-day averages ·
trend checks 6/7
A textbook flag after a breakaway gap. The stock jumped from
about $86 to $103 in mid-August after the Q2 beat and has climbed steadily
since. Bollinger bands are tight at $104–$115, and price sits 2.5% under its
$116.85 high with RSI 64. Volume is running 1.4× normal. A close above $117
would confirm the next leg. The August gap ($86–$100) is support, and a fill
would break the setup.
|
Key level |
Value |
|
Resistance |
$116.85 (high) |
|
Support |
$99.7 (50d) · $86 (gap) |
|
Bollinger 20d |
$103.9 – $115.4 |
|
RSI 14 / MACD |
64 / flat |
|
Off 52-wk high |
−2.5% |
|
Realized vol,
1Y |
36.4% |
Fundamentals
|
Metric |
Value |
|
Q2 2026
revenue |
$481M (+48% y/y) |
|
Q2 EPS vs est. |
$2.28 vs $1.79 |
|
FY26 EPS
guidance |
$8.65 – $9.00 |
|
Operating
margin |
59.8% |
|
Gross margin |
76.3% |
|
Trailing /
forward P/E |
33.4× / 11.0× |
|
EV / EBITDA |
14.2× |
|
New converts
(Sep 17) |
$1.3B, 1.50%, due 2033 |
|
Debt / cash |
$2.18B / $0.23B |
|
Analyst mean
target (n) |
$99.6 (9) |
Peer comparison
|
Ticker |
Price |
Mkt cap |
Fwd P/E |
Rev growth |
Op margin |
3M |
12M |
1Y vol |
To target |
|
HALO |
$113.90 |
$12.9B |
11.0× |
+48% |
+60% |
+52% |
+54% |
36% |
-13% |
|
RPRX |
$58.21 |
$33.6B |
10.2× |
+17% |
+20% |
+4% |
+66% |
23% |
+12% |
|
INCY |
$123.89 |
$25.1B |
13.9× |
+38% |
+42% |
+9% |
+50% |
33% |
+3% |
|
EXEL |
$58.16 |
$14.4B |
13.7× |
+11% |
+40% |
+6% |
+50% |
37% |
-8% |
|
ARGX |
$959.49 |
$59.7B |
27.6× |
+59% |
+32% |
+8% |
+35% |
34% |
+23% |
|
VRTX |
$526.19 |
$133.4B |
26.2× |
+13% |
+38% |
+7% |
+36% |
28% |
+8% |
Royalty Pharma (RPRX) is the closest business model. HALO grows
about 3× faster at a similar forward multiple, with triple the operating
margin. argenx (ARGX) is also a HALO partner through Vyvgart Hytrulo.
Catalysts
•
Keytruda
subcutaneous litigation with Merck: Munich court granted Halozyme a preliminary
injunction in Dec 2025; the US case is ongoing
•
New ENHANZE
and MDASE partner deals extend royalty life
•
Use of the
$1.3B convert proceeds (buyback or acquisition)
Risks
•
ENHANZE
patent expiries later this decade; the bear case is a royalty cliff
•
Litigation
is binary; a loss against Merck removes a large optional upside
•
Convertible
dilution and a leveraged balance sheet (debt/equity above 15×)
Screen scorecard
|
Component |
Score |
|
Composite
score |
75 / 100 |
|
Fundamentals |
24 / 40 |
|
Technicals |
31 / 35 |
|
Risk |
13 / 15 |
|
IBD rank |
8 / 10 |
|
Beta to
S&P 500 |
0.52 |
DEEP DIVE · CRUDE AND PRODUCT TANKERS · SCREEN #5 OF 50 · IBD
RANK 40
INSW International Seaways
$105.64 HOLD
The lower-risk way to hold the tanker trade. INSW runs crude and
product tankers, carries almost no net debt (about 6% of fleet value), and
breaks even near $14,500 a day against Q3 bookings around $61,000. It pays out
at least 85% of adjusted income. Q3 bookings are below Q2's $79,000, so the
dividend likely steps down from $5.05.
Forecast and probability
|
|
1 quarter |
1 year |
|
Target price |
$105.00 |
$100.00 |
|
Change from
today |
-0.6% |
-5.3% |
|
Est. total
return incl. dividends |
+4% |
+9% |
|
P(at or above
target at horizon) |
47% |
49% |
|
MC median
price |
$104 |
$98.66 |
|
MC P10 – P90 |
$81.00 – $133 |
$60.46 – $162 |
|
P(down 20%+ at
1Y) |
– |
35% |
Targets are ex-dividend share prices. Expected total return is
about +4% for the quarter and +9% for the year, including my dividend estimate
of about $4.50 next quarter and $15 over 12 months. The consensus mean is $107
from 6 analysts. Simulation volatility 39%, drift -6.3% a year.
Monte Carlo price fan, next 12 months (log scale)
Technical analysis
One year, weekly closes with 50- and 200-day averages ·
trend checks 6/7
Similar to ECO but less extended. The stock set a record at
$113.14 and pulled back 7% to $105.6. The MACD histogram is negative and volume
is elevated at 1.46× normal. RSI is neutral at 56. The 50-day ($98.3) and lower
Bollinger band ($97.3) form a clear support shelf, and the uptrend holds while
price stays above it.
|
Key level |
Value |
|
Resistance |
$111.7 (BB) · $113.1 (high) |
|
Support |
$98.3 (50d) · $97.3 (BB) |
|
Bollinger 20d |
$97.3 – $111.7 |
|
RSI 14 / MACD |
56 / negative |
|
Off 52-wk high |
−6.6% |
|
Realized vol,
1Y |
38.6% |
Fundamentals
|
Metric |
Value |
|
Q2 2026 adj.
EPS |
$5.91 |
|
Q2 adj. EBITDA
/ FCF |
$345M / $261M |
|
Q2 dividend |
$5.05 (≥85% payout) |
|
Q3 booked |
48% of days at ~$61k/day |
|
Operating
margin |
64.2% |
|
Trailing /
forward P/E |
6.8× / 16.5× |
|
EV / EBITDA |
6.8× |
|
Net debt /
fleet value |
~6% |
|
Cash
break-even |
~$14.5k/day |
|
Analyst mean
target (n) |
$107 (6) |
Peer comparison
|
Ticker |
Price |
Mkt cap |
Fwd P/E |
Rev growth |
Op margin |
3M |
12M |
1Y vol |
To target |
|
INSW |
$105.64 |
$5.2B |
16.5× |
+140% |
+64% |
+33% |
+123% |
39% |
+1% |
|
ECO |
$77.90 |
$3.0B |
13.1× |
+239% |
+75% |
+56% |
+164% |
43% |
-4% |
|
FRO |
$47.73 |
$10.6B |
10.4× |
+97% |
+66% |
+34% |
+107% |
43% |
+6% |
|
TNK |
$94.07 |
$3.3B |
8.6× |
+63% |
+50% |
+38% |
+79% |
39% |
-0% |
|
STNG |
$81.49 |
$4.1B |
15.1× |
+78% |
+60% |
+12% |
+41% |
36% |
+19% |
|
DHT |
$21.78 |
$3.5B |
10.2× |
+96% |
+71% |
+23% |
+77% |
37% |
+0% |
Teekay Tankers (TNK), also in the IBD 50, holds net cash and
trades at 8.6× forward. It is the cheapest name in the group, but it lacks
INSW's product-tanker mix.
Catalysts
•
Q3 results
and dividend in early November
•
Product-tanker
strength (MRs near $35k/day) diversifies away from VLCC spot
•
10 LR1
newbuilds ordered at pre-inflation prices for 2028 delivery
Risks
•
Same
geopolitical driver as ECO; rates would normalize together
•
Q3 rates
already below Q2, so earnings are past their peak
•
Consensus
forward P/E of 16.5× implies EPS roughly halves
Screen scorecard
|
Component |
Score |
|
Composite
score |
72 / 100 |
|
Fundamentals |
30 / 40 |
|
Technicals |
27 / 35 |
|
Risk |
14 / 15 |
|
IBD rank |
2 / 10 |
|
Beta to
S&P 500 |
0.30 |
Full screen, all 50
Sorted by composite score. Top-five picks are highlighted. Trend
= number of 7 trend checks passed. MC range = 1-year P5 / median / P95 as a
multiple of today's price.
|
# |
Ticker |
Name |
Theme |
Score |
IBD |
EPS % |
Sales % |
Price |
3M |
12M |
Off high |
RSI |
Trend |
Vol |
Fwd P/E |
To target |
P(up 1Y) |
P(−25%) |
MC 1Y P5 / P50 / P95 |
|
1 |
MU |
Micron
Technology |
AI hardware |
80 |
12 |
999+ |
346 |
$1,082 |
-4% |
+590% |
-14% |
63 |
6/7 |
81% |
6.8× |
+40% |
53% |
33% |
0.29 / 1.06 / 4.03× |
|
2 |
ECO |
Okeanis Eco
Tankers |
Tankers |
79 |
2 |
612 |
185 |
$77.90 |
+56% |
+164% |
-11% |
59 |
6/7 |
43% |
13.1× |
-4% |
57% |
21% |
0.52 / 1.08 / 2.23× |
|
3 |
NVDA |
NVIDIA |
AI hardware |
76 |
33 |
112 |
106 |
$225.07 |
+17% |
+27% |
-5% |
55 |
7/7 |
38% |
14.4× |
+46% |
57% |
17% |
0.58 / 1.07 / 2.03× |
|
4 |
HALO |
Halozyme
Therapeutics |
Health care |
75 |
10 |
48 |
48 |
$113.90 |
+52% |
+54% |
-3% |
64 |
6/7 |
36% |
11.0× |
-13% |
56% |
19% |
0.57 / 1.06 / 2.11× |
|
5 |
INSW |
International
Seaways |
Tankers |
72 |
40 |
479 |
130 |
$105.64 |
+33% |
+123% |
-7% |
56 |
6/7 |
39% |
16.5× |
+1% |
59% |
18% |
0.56 / 1.09 / 2.05× |
|
6 |
ETON |
Eton
Pharmaceuticals |
Health care |
71 |
1 |
450 |
99 |
$57.68 |
+62% |
+186% |
-13% |
53 |
6/7 |
66% |
22.4× |
+23% |
53% |
32% |
0.31 / 1.06 / 4.03× |
|
7 |
WT |
WisdomTree |
Other |
70 |
3 |
72 |
57 |
$24.33 |
+42% |
+72% |
-6% |
59 |
6/7 |
40% |
18.0× |
+4% |
58% |
19% |
0.55 / 1.09 / 2.14× |
|
8 |
NTAP |
NetApp |
Software |
70 |
17 |
66 |
30 |
$201.15 |
+32% |
+67% |
-4% |
60 |
7/7 |
43% |
18.1× |
-2% |
57% |
20% |
0.54 / 1.08 / 2.22× |
|
9 |
TGTX |
TG
Therapeutics |
Health care |
70 |
18 |
-71 |
70 |
$57.43 |
+3% |
+66% |
-3% |
58 |
7/7 |
45% |
19.4× |
+21% |
57% |
21% |
0.51 / 1.07 / 2.29× |
|
10 |
ERO |
Ero Copper |
Metals &
mining |
66 |
5 |
80 |
74 |
$37.87 |
+43% |
+106% |
-7% |
59 |
7/7 |
64% |
7.9× |
+8% |
56% |
29% |
0.37 / 1.08 / 3.04× |
|
11 |
HNGE |
Hinge Health |
Health care |
66 |
8 |
69 |
53 |
$95.57 |
+21% |
+87% |
-1% |
60 |
6/7 |
55% |
31.3× |
+13% |
55% |
25% |
0.46 / 1.07 / 2.44× |
|
12 |
TNK |
Teekay Tankers |
Tankers |
64 |
45 |
294 |
121 |
$94.07 |
+38% |
+79% |
-9% |
52 |
6/7 |
39% |
8.6× |
-0% |
57% |
18% |
0.56 / 1.07 / 2.07× |
|
13 |
SN |
SharkNinja |
Other |
62 |
19 |
30 |
22 |
$177.74 |
+23% |
+68% |
-9% |
57 |
7/7 |
43% |
23.2× |
+18% |
57% |
20% |
0.55 / 1.07 / 2.16× |
|
14 |
ARGX |
argenx |
Health care |
60 |
34 |
96 |
59 |
$959.49 |
+8% |
+35% |
-11% |
45 |
5/7 |
34% |
27.6× |
+23% |
57% |
18% |
0.57 / 1.08 / 2.08× |
|
15 |
TSM |
Taiwan
Semiconductor |
AI hardware |
60 |
36 |
62 |
24 |
$450.61 |
+4% |
+63% |
-6% |
62 |
6/7 |
40% |
20.6× |
+23% |
59% |
18% |
0.56 / 1.09 / 2.09× |
|
16 |
AUGO |
Aura Minerals |
Metals &
mining |
59 |
6 |
156 |
76 |
$83.57 |
+30% |
+154% |
-24% |
50 |
5/7 |
74% |
10.3× |
+22% |
55% |
31% |
0.32 / 1.09 / 3.79× |
|
17 |
ANET |
Arista
Networks |
AI hardware |
59 |
14 |
40 |
38 |
$206.55 |
+31% |
+44% |
-4% |
60 |
7/7 |
54% |
39.8× |
+17% |
55% |
26% |
0.44 / 1.07 / 2.60× |
|
18 |
SLDE |
Slide
Insurance |
Other |
59 |
31 |
89 |
17 |
$23.10 |
+21% |
+53% |
-14% |
45 |
5/7 |
41% |
6.3× |
+12% |
56% |
20% |
0.55 / 1.07 / 2.13× |
|
19 |
WPM |
Wheaton
Precious Metals |
Metals &
mining |
58 |
23 |
90 |
85 |
$142.92 |
+26% |
+33% |
-14% |
46 |
6/7 |
51% |
28.7× |
+25% |
57% |
23% |
0.47 / 1.10 / 2.48× |
|
20 |
RBRK |
Rubrik |
Software |
57 |
11 |
767 |
38 |
$109.55 |
+52% |
+34% |
-6% |
60 |
7/7 |
65% |
142.7× |
+10% |
54% |
30% |
0.35 / 1.07 / 3.31× |
|
21 |
SCCO |
Southern
Copper |
Metals &
mining |
57 |
13 |
71 |
41 |
$203.92 |
+21% |
+80% |
-8% |
55 |
7/7 |
52% |
28.0× |
-16% |
55% |
24% |
0.47 / 1.07 / 2.48× |
|
22 |
EXEL |
Exelixis |
Health care |
57 |
38 |
21 |
11 |
$58.16 |
+6% |
+50% |
-3% |
56 |
6/7 |
37% |
13.7× |
-8% |
59% |
15% |
0.61 / 1.08 / 1.95× |
|
23 |
AMD |
Advanced Micro
Devices |
AI hardware |
56 |
9 |
246 |
50 |
$630.63 |
+21% |
+291% |
-1% |
73 |
5/7 |
72% |
40.5× |
-2% |
55% |
30% |
0.34 / 1.09 / 3.50× |
|
24 |
ZETA |
Zeta Global |
Software |
56 |
16 |
386 |
44 |
$29.45 |
+55% |
+45% |
-10% |
49 |
6/7 |
66% |
24.4× |
+7% |
55% |
27% |
0.40 / 1.08 / 2.96× |
|
25 |
NEM |
Newmont |
Metals &
mining |
56 |
21 |
47 |
15 |
$121.43 |
+26% |
+45% |
-10% |
48 |
6/7 |
50% |
11.9× |
+13% |
57% |
22% |
0.50 / 1.09 / 2.33× |
|
26 |
SMCI |
Super Micro
Computer |
AI hardware |
56 |
24 |
315 |
93 |
$43.26 |
+41% |
-6% |
-26% |
64 |
6/7 |
95% |
8.1× |
-2% |
53% |
35% |
0.23 / 1.06 / 4.54× |
|
27 |
IAG |
Iamgold |
Metals &
mining |
55 |
22 |
223 |
48 |
$19.70 |
+24% |
+67% |
-21% |
50 |
5/7 |
65% |
8.3× |
+24% |
55% |
28% |
0.40 / 1.08 / 2.93× |
|
28 |
GH |
Guardant
Health |
Health care |
54 |
7 |
n/a |
44 |
$177.25 |
+19% |
+195% |
-3% |
59 |
7/7 |
56% |
n/m |
+11% |
55% |
25% |
0.46 / 1.08 / 2.66× |
|
29 |
FNV |
Franco-Nevada |
Metals &
mining |
54 |
46 |
46 |
57 |
$257.87 |
+20% |
+21% |
-10% |
50 |
6/7 |
39% |
27.6× |
+11% |
57% |
17% |
0.58 / 1.07 / 1.98× |
|
30 |
SNOW |
Snowflake |
Software |
53 |
27 |
77 |
35 |
$335.94 |
+35% |
+52% |
-13% |
55 |
6/7 |
62% |
111.5× |
+27% |
56% |
25% |
0.46 / 1.08 / 2.73× |
|
31 |
DXCM |
DexCom |
Health care |
53 |
28 |
46 |
13 |
$86.62 |
+24% |
+27% |
-6% |
49 |
6/7 |
40% |
27.7× |
+9% |
58% |
18% |
0.56 / 1.08 / 2.07× |
|
32 |
GRMN |
Garmin |
Other |
53 |
39 |
29 |
11 |
$294.14 |
+27% |
+24% |
-6% |
63 |
7/7 |
34% |
26.4× |
+3% |
58% |
16% |
0.59 / 1.08 / 1.98× |
|
33 |
ARIS |
Aris Mining |
Metals &
mining |
52 |
20 |
74 |
60 |
$18.93 |
+25% |
+102% |
-19% |
50 |
4/7 |
64% |
6.4× |
+96% |
55% |
28% |
0.38 / 1.09 / 3.02× |
|
34 |
RGLD |
Royal Gold |
Metals &
mining |
52 |
32 |
41 |
115 |
$252.49 |
+21% |
+31% |
-18% |
53 |
4/7 |
42% |
19.6× |
+22% |
59% |
17% |
0.57 / 1.08 / 2.02× |
|
35 |
PAYC |
Paycom
Software |
Software |
52 |
50 |
35 |
10 |
$220.46 |
+71% |
+3% |
-10% |
51 |
6/7 |
46% |
15.8× |
-1% |
56% |
24% |
0.46 / 1.08 / 2.61× |
|
36 |
NTRA |
Natera |
Health care |
51 |
4 |
n/a |
38 |
$412.56 |
+57% |
+152% |
-1% |
84 |
5/7 |
47% |
n/m |
-14% |
55% |
23% |
0.48 / 1.07 / 2.42× |
|
37 |
MGNI |
Magnite |
Software |
51 |
48 |
30 |
17 |
$23.97 |
+28% |
+7% |
-11% |
51 |
6/7 |
58% |
18.6× |
+20% |
55% |
26% |
0.42 / 1.07 / 2.66× |
|
38 |
LITE |
Lumentum |
AI hardware |
50 |
25 |
267 |
109 |
$941.65 |
+15% |
+492% |
-13% |
54 |
7/7 |
97% |
27.3× |
+22% |
53% |
35% |
0.22 / 1.07 / 5.40× |
|
39 |
PLTR |
Palantir
Technologies |
Software |
50 |
42 |
156 |
93 |
$189.67 |
+68% |
+6% |
-9% |
64 |
7/7 |
59% |
81.7× |
+3% |
54% |
29% |
0.38 / 1.06 / 3.12× |
|
40 |
VEEV |
Veeva Systems |
Health care |
49 |
47 |
18 |
18 |
$280.68 |
+64% |
+0% |
-10% |
67 |
6/7 |
42% |
27.4× |
+6% |
56% |
21% |
0.52 / 1.07 / 2.25× |
|
41 |
SITM |
SiTime |
AI hardware |
46 |
41 |
398 |
127 |
$662.27 |
-2% |
+125% |
-27% |
58 |
5/7 |
84% |
44.4× |
+28% |
54% |
33% |
0.25 / 1.09 / 4.73× |
|
42 |
NET |
Cloudflare |
Software |
45 |
15 |
38 |
36 |
$349.02 |
+47% |
+60% |
-5% |
62 |
7/7 |
66% |
208.2× |
-4% |
56% |
28% |
0.38 / 1.09 / 2.96× |
|
43 |
DDOG |
Datadog |
Software |
45 |
29 |
41 |
36 |
$268.13 |
+12% |
+96% |
-8% |
67 |
6/7 |
68% |
90.2× |
+7% |
53% |
30% |
0.36 / 1.06 / 3.31× |
|
44 |
AU |
AngloGold
Ashanti |
Metals &
mining |
45 |
37 |
57 |
27 |
$99.03 |
+21% |
+51% |
-23% |
44 |
4/7 |
61% |
9.9× |
+18% |
55% |
26% |
0.41 / 1.08 / 2.78× |
|
45 |
CAI |
Caris Life
Sciences |
Health care |
44 |
35 |
100 |
45 |
$31.98 |
+73% |
+8% |
-5% |
74 |
6/7 |
67% |
85.2× |
-12% |
53% |
31% |
0.34 / 1.05 / 3.31× |
|
46 |
ESTC |
Elastic |
Software |
44 |
49 |
17 |
15 |
$88.12 |
+57% |
+4% |
-18% |
53 |
5/7 |
58% |
22.3× |
+26% |
56% |
27% |
0.40 / 1.08 / 2.87× |
|
47 |
AEM |
Agnico Eagle
Mines |
Metals &
mining |
43 |
44 |
57 |
35 |
$194.48 |
+24% |
+22% |
-24% |
49 |
4/7 |
49% |
15.6× |
+11% |
57% |
22% |
0.49 / 1.09 / 2.39× |
|
48 |
BLLN |
BillionToOne |
Health care |
38 |
43 |
999+ |
64 |
$123.08 |
+4% |
– |
-18% |
66 |
5/7 |
96% |
82.9× |
+1% |
55% |
35% |
0.18 / 1.13 / 5.64× |
|
49 |
OUST |
Ouster |
AI hardware |
37 |
30 |
n/a |
56 |
$43.72 |
+4% |
+53% |
-32% |
64 |
5/7 |
104% |
n/m |
+36% |
53% |
37% |
0.17 / 1.08 / 6.70× |
|
50 |
TEM |
Tempus AI |
Health care |
31 |
26 |
n/a |
22 |
$85.01 |
+51% |
+10% |
-19% |
73 |
5/7 |
72% |
n/m |
-19% |
52% |
34% |
0.29 / 1.05 / 4.18× |
Score = fundamentals 40 (IBD EPS and sales growth, operating
margin, ROE, forward P/E, analyst upside) + technicals 35 (7-point trend
template and 6-month return per unit of volatility) + risk 15 (Monte Carlo odds
of a 30% drawdown) + IBD rank 10. Each input is a percentile within the 50.
Trend checks: price above 50-day, 50-day above 200-day, price above 200-day,
50-day rising, within 15% of 52-week high, RSI 45–72, MACD histogram positive.
How the numbers were built
Prices and fundamentals. Two years of daily bars and current valuation fields from Yahoo
Finance, pulled Sep 27, 2026. IBD rank, EPS % change and sales % change come
from the IBD 50 list supplied; IBD caps EPS change at 999%.
Monte Carlo. 20,000
one-year daily paths for each top-five stock (8,000 for the screen). Daily
shocks are bootstrapped from the stock's own last 252 log returns, demeaned so
past momentum does not leak into the forecast, then rescaled to a volatility
that blends 1-year and 3-month realized vol. This keeps the fat tails of the
real return distribution.
Drift. A
market-neutral 8% a year, minus the expected dividend yield for the two tankers
(ECO 20%, INSW 14%), since their share price drops on each ex-date. The
probabilities answer: if the stock only earns a market-like return, how likely
is it to reach the target by chance and volatility alone?
Forecast targets. Base case for each stock, set from forward earnings, a multiple
the market is likely to pay, and where consensus sits. Consensus targets lag
price, so they carry less weight for names that have just rerated.
Two probability measures. “At horizon” is the share of paths at or above the target
on the last day of the quarter or year. “Touch” is the share that trade at or
above it at any point first, which matters if you would sell into the target.
Limits. Bootstrapped
volatility cannot foresee regime breaks: a ceasefire that collapses tanker
rates, a memory-price downturn, or a patent ruling. Tanker dividend estimates
are estimates, not company guidance. This is research to support your own
decisions, not investment advice.
Sources
Investing.com — Micron earnings outlook ahead of Sep 30 — https://www.investing.com/news/stock-market-news/micron-earnings-outlook-what-to-watch-ahead-of-the-september-30-report-93CH-4911385
TradingKey — Micron Q4 earnings preview — https://www.tradingkey.com/analysis/stocks/us-stocks/262188101-mu-dram-hbm-skhynix-samsung-tradingkey
Webull — Nvidia Q2 FY2027 results and Q3 guide — https://www.webull.com/blog/304-Nvidia-Q2-FY2027-Earnings-Beats-Revenue-EPS-Estimates-Guides-Q3-to-108B
Motley Fool — Is Nvidia a buy in September 2026? — https://www.fool.com/investing/2026/09/15/is-nvidia-stock-a-buy-in-september-2026/
Yahoo Finance — Oil tanker rates top $1 million a day — https://finance.yahoo.com/markets/commodities/articles/oil-tanker-rates-top-1-123500215.html
Yahoo Finance — Okeanis Eco Tankers Q2 call highlights — https://finance.yahoo.com/markets/stocks/articles/okeanis-eco-tankers-q2-earnings-050348781.html
Yahoo Finance — International Seaways Q2 2026 call — https://finance.yahoo.com/markets/stocks/articles/international-seaways-insw-q2-2026-144401730.html
ad-hoc-news — Halozyme Q2 growth and convertible notes — https://www.ad-hoc-news.de/boerse/news/nebenwerte/halozyme-stock-falls-2-34-percent-after-strong-quarterly-growth/70171343
pharmaphorum — German court blocks Keytruda SC launch — https://pharmaphorum.com/news/setback-msd-german-court-blocks-keytruda-sc-launch
Yahoo Finance — price history, quotes and financial data (Sep
27, 2026) — https://finance.yahoo.com/
Comments
Post a Comment